This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
amplification The replication of a biomolecule, in particular the production of one or more copies of a nucleic acid sequence, known as an amplicon, either naturally (e.g. by spontaneous duplications) or artificially (e.g. by PCR), and especially implying many repeated replication events resulting in thousands, millions, or billions of copies of the target sequence, which is then said to be amplified.
The term "base" appears to have been first used in 1717 by the French chemist, Louis Lémery, as a synonym for the older Paracelsian term "matrix." In keeping with 16th-century animism, Paracelsus had postulated that naturally occurring salts grew within the earth as a result of a universal acid or seminal principle having impregnated an earthy matrix or womb. ... Its modern meaning and general introduction into the chemical vocabulary, however, is usually attributed to the French chemist, Guillaume-François Rouelle. ... In 1754 Rouelle explicitly defined a neutral salt as the product formed by the union of an acid with any substance, be it a water-soluble alkali, a volatile alkali, an absorbent earth, a metal, or an oil, capable of serving as "a base" for the salt "by giving it a concrete or solid form." Most acids known in the 18th century were volatile liquids or "spirits" capable of distillation, whereas salts, by their very nature, were crystalline solids. Hence it was the substance that neutralized the acid which supposedly destroyed the volatility or spirit of the acid and which imparted the property of solidity (i.e., gave a concrete base) to the resulting salt.
The extent to which psilocin (and by extension psilocybin) is metabolized by MAO, specifically MAO-A, is not fully clear, but has ranged from 4% to 33% in different studies based on metabolite excretion. However, circulating levels of the deaminated metabolite of psilocin are far higher than those of free unmetabolized psilocin with psilocybin administration. An early clinical study of psilocybin in combination with short-term tranylcypromine pretreatment found that tranylcypromine marginally potentiated the peripheral effects of psilocybin, including pressor effects and mydriasis, but overall did not significantly modify the psychoactive and hallucinogenic effects of the psilocybin, although some of its emotional effects were said to be reduced and some of its perceptual effects were said to be amplified. Some psychedelics are substrates of cytochrome P450 (CYP450) enzymes, for instance LSD being a substrate of CYP2D6 as well as of several other CYP450 enzymes. As such, CYP450 inhibitors may increase exposure to CYP450-substrate psychedelics such as LSD and thereby potentiate their effects as well as risks. A clinical study found that administration of LSD to people taking paroxetine, a selective serotonin reuptake inhibitor (SSRI) and strong CYP2D6 inhibitor, increased LSD exposure by about 1.5-fold. The combination was well-tolerated and did not modify the pleasant subjective effects or physiological effects of LSD, whereas negative effects of LSD, including "bad drug effect", anxiety, and nausea, were reduced.
Sources: en.wikipedia.org
The top management of Lyons, with its background in the use of mechanical adding machines, saw the necessity of new electrical computers for organising the distribution of cakes and other highly perishable goods. They, therefore, substantially financed the University of Cambridge's Electronic Delay Storage Automatic Calculator (EDSAC) which was the second electronic digital stored-program computer to go into regular service, and built their own programmable digital computers. They became the first user of these in businesses, with the LEO I digital computer: the Lyons Electronic Office I, designed and built by Dr John Pinkerton under the leadership of John Simmons. It handled the company's accounts and logistics. Lyons also included the weather forecast to ensure goods carried by their "fresh produce" delivery vans were not wasted in large quantities. Google chairman Eric Schmidt called this "the world's first office computer", built in 1951. A subsidiary LEO Computers Ltd was formed in 1954 and went on to build 11 Leo II and 94 Leo III computers that were sold worldwide. One of the ardent users of LEO computers was the General Post Office (GPO), who bought them in the mid/late 1960s to produce telephone bills. They were kept going until 1981, helped by buying other companies' redundant machines and using them for spare parts.
First place was won by a team that built a remote controlled balloon, which took the group four 15 to 18 hour days to build, that carried a video camera and drill built to take a sample. It was modeled after technology used in planetary exploration. They received $250 and a lithograph of a drawing of the Great Pumpkin autographed by Charles Schulz. Multiple theories were proposed as to how the pumpkin was placed on the tower, including by helicopter. The university's president Hunter R. Rawlings III, who was over 6 feet (1.8 m) tall, joked that "it was me," and that he "stood on [his] tippy toes." Despite this, the university also stated it would consider bringing charges against whoever placed the pumpkin, and campus police investigated the incident. However, some students proposed amnesty for the culprit. One archivist for the university offered to take a sealed envelope containing the name of the person who placed the pumpkin and open it in 5 or 10 years. The pumpkin stayed at the top of the tower until springtime, slowly rotting.
The first instance of a pathogenic NAA20 variant were two siblings with a Met54Val missense mutation and three siblings with a homozygous missense variant Ala80Val, and the second instance was about two siblings with a Gln34Ter/Leu4Pro biallelic mutation. The common effect of these mutations is that there is weaker binding of NAA20 to NAA25, thereby reducing the capacity of the NatB complex to add an acetyl group to a target protein. There are some slight differences in the clinical symptoms in the seven patients, the main one is that the patients with either Met54Val or Ala80Val mutation had decreased head circumference, a condition known as microcephaly. The common symptoms in all seven patients are various forms of developmental delay in form of speech impairment, walking disabilities and changes in facial features. Which proteins are affected and could cause the pathogenic symptoms is to date not known and must be further studied, since the effect of NAA20 loss of function is quite impactful to the patients' health and quality of life.
The addition of the cyano group generally increases the potency. Therefore, researchers' attention was directed to those compounds. Usually, DPP-4 inhibitors are either substrate-like or non-substrate-like.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.